Click here for Somavert® (pegvisomant) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
Somavert is used in the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-I concentrations or was not tolerated.
This animation explains how to start new patients using the AcroCare service
This animation explains how to start new Somavert patients using a standard homecare service
This animation explains how to set up new Somavert patients where no homecare is available or the patient chooses not to receive it
Specialist nurse support from day one
Vicky Ruszala, Specialist Pharmacist in Diabetes and Endocrinology, North Bristol NHS Trust explains the main roles of the pharmacist from medicines optimisation and BlueTeq funding arrangements to homecare service provision
Find information on funding, initiation, homecare and follow-up
To find out more about ACRODAT supporting your patients or to order starter kits
Sherwin Criseno, Consultant Endocrinology Nurse, University Hospital of Birmingham, discusses how nurses can support people with acromegaly from diagnosis through ongoing management.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020